How Ozempic is affecting people with eating disorders and the food industry
UC expert discusses need for more research with WVXU's Cincinnati Edition
GLP-1 drugs, sold under brand names including Ozempic and Wegovy, are growing more popular for weight loss. At the same time, experts say the drugs are dramatically altering people's relationship with food and the food and beverage industry itself.
The University of Cincinnati's Susan McElroy, MD, told WVXU's Cincinnati Edition that a trial she led found that liraglutide, a drug in the GLP-1 class, was efficacious for weight loss for individuals with bipolar disorder and statistically reduced binge eating behavior based on self-reported data.
However, McElroy said that in general, it is difficult to conduct research focusing on GLP-1's effect on mental health and eating disorders.
"I’m just really sad that the GLP-1 companies haven’t taken eating disorders seriously," said McElroy, the Linda and Harry Fath endowed professor in the Department of Psychiatry & Behavioral Neuroscience in UC’s College of Medicine, chief research officer at the Lindner Center of HOPE and a UC Health physician.
Anecdotally, McElroy said some patients have reported GLP-1s triggering anorexia, while others say the drugs have been the only solution to address binge eating disorder. The wide range of outcomes highlights the need for more thorough research, she said.
"The industry has basically ignored eating disorders," she said. "I guess they assume that by getting at obesity they’re going to get most of the people with eating disorders, but that’s just not the truth."
Listen to the Cincinnati Edition segment.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
Pocket-sized population threat
June 10, 2026
The Financial Times took a deep dive into why populations around the world continue to be on the decline. The publication cited new University of Cincinnati research as part of the investigation that looks at the fall of fertility in the digital era.
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.